Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

Conditions: Neuroendocrine Tumors; Neuroendocrine Tumor of the Lung; Neuroendocrine Tumor of Pancreas; Neuroendocrine Carcinoma Metastatic; Neuroendocrine Tumor Carcinoid; Carcinoid Tumor of GI System; Carcinoid Tumor; Paraganglioma; Pheochromocytoma
Interventions: Drug: [212Pb]VMT-α-NET; Drug: [212Pb]VMT-α-NET
Sponsors: Viewpoint Molecular Targeting
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 9, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments